ResearchSafe

EPO (Erythropoietin (EPO))

Category: Muscle Growth. Status: FDA-approved drug (prescription).

A glycoprotein hormone that stimulates red blood cell production. Medically used for anemia, it is also notorious as a banned endurance-enhancing agent. Included here for educational reference on its mechanism and significant risks.

How it works

Binds erythropoietin receptors on bone marrow progenitor cells, stimulating proliferation and maturation of red blood cells. More red cells raise oxygen-carrying capacity, but also thicken the blood.

Key facts

  • Molecular weight: ~34 kDa (glycosylated)
  • Half-life: ~4-13 hours (varies by formulation)
  • Bioavailability: Subcutaneous or intravenous injection
  • Storage: Refrigerate 2-8°C; do not freeze.

Dosing overview

  • Typical dose: Prescription-only, condition-specific
  • Frequency: Per medical protocol
  • Duration: Per medical protocol
  • Route: Subcutaneous or IV injection

Protocol notes

  • Clinical dosing is individualized by a physician based on hemoglobin and the condition being treated.
  • Non-medical/performance use is banned in sport and carries serious cardiovascular risk.
  • Requires monitoring of hematocrit and blood pressure.

Reported benefits

  • Increases red blood cell production
  • Treats anemia (medical use)
  • Raises oxygen-carrying capacity

Possible side effects

  • Blood clots/thrombosis
  • Stroke and heart attack risk
  • Hypertension
  • Increased blood viscosity
  • Banned in competitive sport

Research

  • Erythropoietin in anemia management (2018): Effectively raised hemoglobin in anemia of chronic kidney disease, with dose-dependent cardiovascular risk.

Compare EPO

Community discussions about EPO

Research and educational reference only. Not medical advice.